Anmol Drugs & Pharmaceuticals
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Weaknesses
1- Company has low interest coverage ratio.
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Quarterly Results
| Particulars | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Sales | 9.02 | 5.48 | 26.35 | 13.83 | 11.06 | 14.84 |
| Expenses | 5.03 | 3.58 | 15.19 | 8.98 | 16.27 | 10.12 |
| Operating Profit | 3.99 | 1.9 | 11.16 | 4.85 | -5.21 | 4.72 |
| OPM % | 44.24% | 34.67% | 42.35% | 35.07% | -47.11% | 31.81% |
| Other Income | 0.1 | 0.03 | 0.77 | 0.43 | 0.41 | 0.76 |
| Interest | 0.07 | 0.14 | 0.24 | 0.37 | 1.08 | 1.32 |
| Depreciation | 0.7 | 1.28 | 2.72 | 3.55 | 4.35 | 3.07 |
| PBT | 3.32 | 0.51 | 8.97 | 1.36 | -10.23 | 1.09 |
| Tax % | 24.4% | 23.53% | 25.42% | 25.74% | -23.46% | -38.53% |
| Net Profit | 2.51 | 0.39 | 6.69 | 1.02 | -7.83 | 1.51 |
| EPS (₹) | 5.02 | 0.16 | 2.75 | 0.42 | -3.21 | 0.62 |
Profit & Loss
| Particulars | Mar 2006 |
|---|---|
| Sales | 0 |
| Expenses | 0.02 |
| Operating Profit | -0.02 |
| Other Income | 0.04 |
| Interest | 0.02 |
| Depreciation | 0.01 |
| PBT | -0.01 |
| Tax % | 0% |
| Net Profit | -0.01 |
| Div. Payout % | 0% |
Balance Sheet
| Particulars | Mar 2006 |
|---|---|
| Equity Capital | 6.66 |
| Reserves | -8.05 |
| Borrowings | 0.19 |
| Other Liabilities | 1.54 |
| Total Liabilities | 0.34 |
| Fixed Assets | 0.2 |
| CWIP | 0 |
| Investments | 0 |
| Other Assets | 0.14 |
| Total Assets | 0.34 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Operating | -0.13 | -0.08 | 0.83 | -14.72 | -10.13 |
| Investing | -0.26 | -0.56 | -5.84 | -13.24 | -9.83 |
| Financing | 0.4 | 0.95 | 14.89 | 39.1 | 16.02 |
| Net Cash Flow | 0.01 | 0.32 | 9.88 | 11.13 | -3.94 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 56.15 | 37.07 | 202 | 217 | 262 |
| Inventory Days | — | — | — | 529 | 2,566 |
| Days Payable | — | — | — | 1,080 | 306 |
| Cash Conversion Cycle | 56.15 | 37.07 | 202 | -334 | 2,522 |
| Working Capital Days | 150 | 76.99 | 91.63 | 299 | 369 |
| ROCE % | — | 25.11% | 33.16% | 23.28% | -10.52% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Anmol Drugs & Pharmaceuticals insights
33 extracted metrics + investor summaries across FY06–FY26.
Documents
Frequently Asked Questions about Anmol Drugs & Pharmaceuticals
Where is Anmol Drugs & Pharmaceuticals Ltd (524778) listed?
Company Information
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524778.md for Anmol Drugs & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.